Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19

Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Judith A. Shovel, Mary Kay Wisniewski, Michelle Adam, Debbie Albin, Tami Minnier, Mark Schmidhofer, Russell Meyers, Oscar C. Marroquin, Kevin Collins, William Garrard, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Kelsey Linstrum, Anna Nakayama, Stephanie K. Montgomery, Graham M. Snyder, Donald M. Yealy, Derek C. Angus, Paula L. Kip, Christopher W. Seymour, David T. Huang, Kevin E. Kip
doi: https://doi.org/10.1101/2021.11.30.21266756
Erin K. McCreary
1Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mccrearye3@upmc.edu
J. Ryan Bariola
1Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Wadas
2Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith A. Shovel
3Wolff Center, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Kay Wisniewski
3Wolff Center, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Adam
2Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debbie Albin
4Supply Chain Management/HC Pharmacy, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tami Minnier
3Wolff Center, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Schmidhofer
5Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell Meyers
2Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar C. Marroquin
6Clinical Analytics, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Collins
6Clinical Analytics, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Garrard
6Clinical Analytics, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay R. Berry
7Berry Consultants, Austin, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Berry
7Berry Consultants, Austin, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy M. Crawford
7Berry Consultants, Austin, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna McGlothlin
7Berry Consultants, Austin, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelsey Linstrum
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Nakayama
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie K. Montgomery
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham M. Snyder
1Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald M. Yealy
2Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek C. Angus
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
10Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula L. Kip
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher W. Seymour
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
9Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David T. Huang
2Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
8Office of Healthcare Innovation, UPMC, Pittsburgh, PA, USA
9Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
10Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin E. Kip
6Clinical Analytics, UPMC, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous administration may expand outpatient treatment capacity and qualified staff available to administer treatment, but association with patient outcomes is understudied.

Objective To evaluate whether or not, i.) subcutaneous casirivimab and imdevimab treatment is associated with reduced 28-day hospitalization/death than non-treatment among mAb-eligible patients, and ii.) subcutaneous casirivimab and imdevimab treatment is clinically and statistically similar to intravenous casirivimab and imdevimab treatment.

Design, Setting, and Participants Prospective cohort study of outpatients in a learning health system in the United States with mild to moderate COVID-19 symptoms from July 14 to October 26, 2021 who were eligible for mAb treatment under emergency use authorization. A nontreated control group of eligible patients was also selected.

Intervention Subcutaneous injection or intravenous administration of the combined single dose of casirivimab 600mg and imdevimab 600mg.

Main Outcomes and Measures The primary outcome was the 28-day adjusted risk ratio or adjusted risk difference for hospitalization or death. Secondary outcomes included 28-day adjusted risk ratios/differences of hospitalization, death, composite endpoint of ED admission and hospitalization, and rates of adverse events.

Results Among 1,956 matched adults with mild to moderate COVID-19, patients who received casirivimab and imdevimab subcutaneously had a 28-day rate of hospitalization/death of 3.4% (n=652) compared to 7.8% (n=1,304) in nontreated controls [risk ratio 0.44 (95% confidence interval: 0.28 to 0.68, p < .001)]. Among 2,185 patients treated with subcutaneous (n=969) or intravenous (n=1,216) casirivimab and imdevimab, the 28-day rate of hospitalization/death was 2.8% vs. 1.7%, respectively which resulted in an adjusted risk difference of 1.5% (95% confidence interval: -0.5% to 3.5%, p=.14). The 28-day adjusted risk differences (subcutaneous – intravenous) for death, ICU admission, and mechanical ventilation were 0.3% or less, although the 95% confidence intervals were wide.

Conclusions and Relevance Subcutaneously administered casirivimab-imdevimab is associated with reduced risk-adjusted hospitalization or death amongst outpatients with mild to moderate COVID-19 compared to no treatment and indicates low adjusted risk difference compared to patients treated intravenously.

Question Among outpatients with mild to moderate COVID-19, is subcutaneously administered casirivimab and imdevimab associated with improved risk-adjusted 28-day clinical outcomes compared to non-treatment with monoclonal antibodies, and clinically similar association compared to intravenously administered casirivimab and imdevimab?

Findings Among 1,956 propensity-matched adults, outpatients who received casirivimab and imdevimab subcutaneously had a 28-day rate of hospitalization or death of 3.4% (n=652) compared to 7.8% (n=1,304) in non-treated controls [risk ratio 0.44 (95% confidence interval: 0.28 to 0.68, p < .001)]. Among 2,185 outpatients who received subcutaneous (n=969) or intravenous (n=1,216) casirivimab and imdevimab, the 28-day rate of hospitalization/death was 2.8% vs. 1.7%, respectively, which resulted in an adjusted risk difference of 1.5% (95% confidence interval: -0.5% to 3.5%, p=.14). The 28-day adjusted risk differences comparing subcutaneous to intravenous route for death, ICU admission, and mechanical ventilation were 0.3% or less, although the 95% confidence intervals were wide.

Meaning Subcutaneously administered casirivimab and imdevimab is associated with reduced hospitalization or death amongst outpatients with mild to moderate COVID-19 compared to no treatment, and has a small, adjusted risk difference compared to patients treated intravenously.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04790786

Funding Statement

This work did not receive external funding. The U.S. federal government provided the monoclonal antibody treatment reported in this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UPMC Quality Improvement Review Committee (Project ID 3629) and the University of Pittsburgh Institutional Review Board (STUDY21100151)gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This work did not receive external funding. The U.S. federal government provided the monoclonal antibody treatment reported in this manuscript.

  • Conflict of Interest: None of the authors received any payments or influence from a third-party source for the work presented.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 01, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Judith A. Shovel, Mary Kay Wisniewski, Michelle Adam, Debbie Albin, Tami Minnier, Mark Schmidhofer, Russell Meyers, Oscar C. Marroquin, Kevin Collins, William Garrard, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Kelsey Linstrum, Anna Nakayama, Stephanie K. Montgomery, Graham M. Snyder, Donald M. Yealy, Derek C. Angus, Paula L. Kip, Christopher W. Seymour, David T. Huang, Kevin E. Kip
medRxiv 2021.11.30.21266756; doi: https://doi.org/10.1101/2021.11.30.21266756
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Judith A. Shovel, Mary Kay Wisniewski, Michelle Adam, Debbie Albin, Tami Minnier, Mark Schmidhofer, Russell Meyers, Oscar C. Marroquin, Kevin Collins, William Garrard, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Kelsey Linstrum, Anna Nakayama, Stephanie K. Montgomery, Graham M. Snyder, Donald M. Yealy, Derek C. Angus, Paula L. Kip, Christopher W. Seymour, David T. Huang, Kevin E. Kip
medRxiv 2021.11.30.21266756; doi: https://doi.org/10.1101/2021.11.30.21266756

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)